EMAIL THIS PAGE TO A FRIEND

Cancer research

Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain.


PMID 25511375

Abstract

Breast cancer brain metastasis is resistant to therapy and a particularly poor prognostic feature in patient survival. Altered metabolism is a common feature of cancer cells, but little is known as to what metabolic changes benefit breast cancer brain metastases. We found that brain metastatic breast cancer cells evolved the ability to survive and proliferate independent of glucose due to enhanced gluconeogenesis and oxidations of glutamine and branched chain amino acids, which together sustain the nonoxidative pentose pathway for purine synthesis. Silencing expression of fructose-1,6-bisphosphatases (FBP) in brain metastatic cells reduced their viability and improved the survival of metastasis-bearing immunocompetent hosts. Clinically, we showed that brain metastases from human breast cancer patients expressed higher levels of FBP and glycogen than the corresponding primary tumors. Together, our findings identify a critical metabolic condition required to sustain brain metastasis and suggest that targeting gluconeogenesis may help eradicate this deadly feature in advanced breast cancer patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

50299
(−)-Epigallocatechin gallate, ≥97.0% (HPLC)
C22H18O11
93894
(−)-Epigallocatechin gallate, analytical standard
C22H18O11
E4143
(−)-Epigallocatechin gallate, ≥95%
C22H18O11
E4268
(−)-Epigallocatechin gallate, ≥80% (HPLC), from green tea
C22H18O11
94640
DL-Valine, ReagentPlus®, ≥99.0% (NT)
C5H11NO2
V0375
DL-Valine, ≥97% (TLC)
C5H11NO2
W344400
DL-Valine, ≥97%
C5H11NO2
03970590
Epigallocatechin gallate, primary pharmaceutical reference standard
C22H18O11
PHR1333
Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material
C22H18O11
I0460000
Isoleucine, European Pharmacopoeia (EP) Reference Standard
C6H13NO2
W527602
L-Isoleucine, 99%, FCC, FG
C6H13NO2
I5281
L-Isoleucine, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C6H13NO2
I2752
L-Isoleucine, reagent grade, ≥98% (HPLC)
C6H13NO2
PHR1099
L-Isoleucine, Pharmaceutical Secondary Standard; Certified Reference Material
C6H13NO2
I7403
L-Isoleucine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
C6H13NO2
58879
L-Isoleucine, BioUltra, ≥99.5% (NT)
C6H13NO2
56241
L-Isoleucine, certified reference material, TraceCERT®
C6H13NO2
I2877
L-Isoleucine: D-allo-isoleucine
C6H13NO2
V0030000
Valine, European Pharmacopoeia (EP) Reference Standard
C5H11NO2